display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)
mNSCLC - L2 - all populationmNSCLC - L2 - PDL1 positive
atezolizumab alone OAK ... POPLAR OAK ...

Study type: